S1881 Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Interim Results for 2 Years From the ASSURE Study
Bibliographic record
Abstract
Introduction: Seladelpar reduces biochemical markers of cholestasis and pruritus in patients (patients) with primary biliary cholangitis (PBC). ASSURE (NCT03301506) is an ongoing, open label, long-term Phase (Ph) 3 trial of seladelpar in patients rolling over from the Ph 3 registrational study RESPONSE (NCT04620733) or with prior participation in legacy studies (Ph 3 ENHANCE [NCT03602560], CB8025-21629 [NCT02955602], CB8025-31731 [NCT03301506], and CB8025-21838 [NCT04950764]). Here, we report interim 2-year efficacy and safety results. Methods: Patients with insufficient response/intolerance to first-line PBC treatment ursodeoxycholic acid and past participation in a seladelpar clinical trial could enroll in ASSURE. Key endpoints were the composite biochemical response (alkaline phosphatase [ALP] < 1.67× upper limit of normal [ULN], ALP decrease ≥15%, and total bilirubin ≤ULN) and ALP normalization. Pruritus was measured via numerical rating scale (NRS; 0–10). For patients entering ASSURE from RESPONSE, baseline (BL) was entry to RESPONSE and analyzed as continuous seladelpar or crossover from placebo (PBO); legacy patients were analyzed separately, with BL defined as entry to ASSURE. Results: As of 01/31/2024, 158 (RESPONSE) and 179 (legacy) patients received seladelpar 10 mg daily for up to 155 weeks in ASSURE. In RESPONSE, 61.7% (79/128) of seladelpar patients met the composite endpoint at 12 months (M) vs 20% (13/65) for PBO. With continued treatment in ASSURE, 61.8% (63/102) at 6M and 72.4% (21/29) at 12M met the composite endpoint. Among PBO patients crossing over to seladelpar, 75% (39/52) at 6M and 93.8% (15/16) at 12M met the composite endpoint. ALP normalized in 25% of seladelpar and 0 PBO patients at 12M in RESPONSE. With continued treatment, 33.3% (6M) and 17.2% (12M) had ALP normalization; for crossover patients, 26.9% and 50% had ALP normalization. Change from BL in pruritus NRS with seladelpar in ASSURE was similar to RESPONSE: −3.8 and −3.7 at 6M in continuous and crossover patients, respectively, corresponding to the key secondary endpoint in RESPONSE. Among legacy patients, 73.2% (120/164) and 69.7% (69/99) met the composite endpoint at 12M and 24M in ASSURE; at 12M and 24M, 42.1% and 42.4% achieved ALP normalization and change from BL in pruritus NRS was −3.8 and −3.1, respectively. There were no treatment-related serious adverse events. Conclusion: Continuous treatment with seladelpar for RESPONSE and legacy patients led to sustained effects on biochemical markers and pruritus. Seladelpar appeared safe and well tolerated with long-term use.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.002 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.009 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".